Albuterol Sulfate Solution
Product Images NDC 64980-644

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Albuterol Sulfate (NDC 64980-644). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Albuterol Sulfate depicting two albuterol molecules complexed with sulfuric acid (H2SO4). The structure shows the phenol group, hydroxyl groups, and tert-butylamino functional groups characteristic of albuterol.*
FDA Label Image

Carton Back Panel (Carton Back Panel)

Carton Back Panel (Carton Back Panel)
Patient usage instructions for Albuterol Sulfate respiratory inhalation solution are shown, including steps to remove the vial, connect and use the nebulizer, and clean the device. Storage instructions specify keeping the solution between 20°C to 25°C and protecting it from light. The label notes the vial size as 3 mL single-dose, ready-to-use, with usage cautions and age recommendations.*
FDA Label Image

Carton-0.63mg (Carton 0.63mg)

Carton-0.63mg (Carton 0.63mg)
Albuterol Inhalation Solution USP 0.021% 0.63 mg/3 mL packaging label for oral inhalation use, containing 30 sterile unit-dose vials. The label shows the product is distributed by Rising Pharma Holdings, Inc and manufactured by Nephron in West Columbia, SC.*
FDA Label Image

Carton-1.25mg (Carton 1.25mg)

Carton-1.25mg (Carton 1.25mg)
Label for Albuterol Inhalation Solution USP 0.042%, 1.25 mg per 3 mL, a respiratory inhalation solution. The label states it is sterile, prefilled with normal saline for oral inhalation only, and dispensed as 25 unit-dose vials of 3 mL each. Distributed by Rising Pharma Holdings, Inc. and manufactured by Nephron Pharmaceuticals.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
Line graph titled '% Change from Pre-Dose FEV1 Intent-to-Treat Population Day 1' displaying percent change on the y-axis and hours from pre-dose on the x-axis up to 6 hours. It compares three treatments: albuterol 1.25 mg, albuterol 0.63 mg, and placebo. Both albuterol doses show an initial increase in percent change from pre-dose FEV1, peaking near 1 hour then gradually declining, whereas placebo remains relatively flat with minimal change over time.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line graph titled '% Change from Pre-Dose FEV1 Intent-to-Treat Population Day 28' showing the percentage change over time from pre-dose to 6 hours post-dose. The graph compares three treatments: albuterol 1.25 mg, albuterol 0.63 mg, and placebo. The y-axis represents percentage change, and the x-axis represents hours from pre-dose. Both albuterol doses show a higher percentage change compared to placebo over time, with values declining after peak effect.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
An instructional illustration showing a nebulizer setup for respiratory inhalation solution. The image depicts a liquid medication vial being poured into a nebulizer reservoir connected to mouthpiece tubing and a compressed air source via a tube.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
An instructional diagram showing the assembly or connection of parts for a respiratory inhalation solution device, likely related to Albuterol Sulfate solution. The image depicts components of an inhaler or nebulizer, illustrating how to attach or prepare the device for use.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
An instructional illustration showing a person using a respiratory inhalation device. The person holds the inhalation apparatus near their mouth with one hand activating the device, demonstrating proper use technique for inhalation therapy.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
Instructional line drawing showing a person holding an inhalation solution device near their mouth, demonstrating the proper method for respiratory inhalation using the product.*
FDA Label Image

Pouch Label-0.63mg (Pouch Label 0.63mg)

Pouch Label-0.63mg (Pouch Label 0.63mg)
The label is for Albuterol Inhalation Solution, USP 0.021% with a strength of 0.63 mg/3 mL. It is a solution dosage form for oral inhalation supplied in a one 3 mL unit-dose vial. The label includes patient instructions for use, active and inactive ingredients, storage conditions, dosage warnings, and distributor information for Rising Pharma Holdings, Inc.*
FDA Label Image

Pouch Label-1.25mg (Pouch Label 1.25mg)

Pouch Label-1.25mg (Pouch Label 1.25mg)
Albuterol Inhalation Solution USP 0.042%, 1.25 mg per 3 mL unit-dose vial label. The label includes dosage strength, usage instructions for oral inhalation only, active and inactive ingredients, storage conditions, and patient instructions. Distributed by Rising Pharma Holdings, Inc, East Brunswick, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.